NCT00109057已完成2 期
An Open-Label, Multicenter Extension Study of Recombinant Humanized Monoclonal Anti-VEGF Antibody (rhuMAb VEGF, Bevacizumab) in Subjects Treated With rhuMAb VEGF in a Previous Genentech-Sponsored Phase I or Phase II Cancer Study
适应症
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 56
研究概览
简要总结
This is a multicenter, open-label extension study. Subjects who have received rhuMAb VEGF (Avastin) therapy in any Genentech-sponsored Phase I or Phase II cancer study and who did not show evidence of disease progression at completion of the parent study will be eligible for inclusion in this trial.
研究设计
- 研究类型
- Interventional
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Previous participation in and completion of a Genentech-sponsored rhuMAb VEGF Phase I or Phase II cancer study
- •No evidence of progressive disease at completion of the parent study
- •For women of childbearing potential, use of an effective means of contraception
- •Signed informed consent
排除标准
- •Any unresolved or irreversible rhuMAb VEGF-related ongoing serious adverse events occurring during the parent study
- •Any history of central nervous system disease (e.g., primary brain tumor or seizures within 12 months of the first infusion on this study), and/or any evidence of brain metastases
- •Compromised renal or hepatic function, as defined in the parent protocol
- •Anemia, neutropenia, or thrombocytopenia, as defined in the parent protocol
- •Pregnancy (positive pregnancy test) or lactation
- •Current, recent (within 4 weeks of the first infusion of this study), or planned participation in an experimental drug study other than a Genentech-sponsored rhuMAb VEGF cancer study
- •Recent (within 3 weeks of the first infusion of this study) major surgical procedure, biopsy of a parenchymal organ, or significant traumatic injury
- •Clinically significant cardiovascular disease (e.g., uncontrolled hypertension [blood pressure of >160/110 mmHg on medication], myocardial infarction, unstable angina), New York Heart Association (NYHA) Grade II or greater congestive heart failure, serious cardiac dysrhythmia requiring medication, or peripheral vascular disease (Grade II or greater)
- •Serious, nonhealing wound, ulcer, or bone fracture
- •Current or recent (within 10 days of the first infusion on this study) use of oral or parenteral anticoagulants or aspirin (except as required to maintain patency of permanent indwelling intravenous [IV] catheters)
- •Inability to comply with study and/or follow-up procedures
- •History of other disease, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of an investigational drug or that might affect the interpretation of the results of the study or render the subject at high risk from treatment complications
研究者
相似试验
已完成
3 期
A Study to Evaluate Avastin in Patients Treated in a Previous Genentech-Sponsored Cancer StudyMetastasesColorectal CancerBreast CancerNCT00096967Genentech, Inc.100
已完成
4 期
An Extension (Rollover) Study of Vemurafenib in Participants With BRAF V600 Mutation-Positive Malignancies Previously Enrolled in an Antecedent Vemurafenib ProtocolNeoplasmsNCT01739764Hoffmann-La Roche215
已完成
2 期
Extension Study of Long-term Safety and Efficacy of Myozyme in Patients With Pompe Disease Who Were Previously Enrolled in Genzyme Sponsored Enzyme Replacement Therapy (ERT) StudiesPompe Disease Infantile-OnsetGlycogen Storage Disease Type IINCT00763932Genzyme, a Sanofi Company7
已完成
4 期
Study Evaluating the Combination of Etanercept and Methotrexate in Rheumatoid Arthritis SubjectsRheumatoid ArthritisNCT00252668Wyeth is now a wholly owned subsidiary of Pfizer300
已完成
不适用
An Extension Study to Evaluate the Safety and Tolerability of Ranibizumab in Subjects With Choroidal Neovascularization Secondary to AMD or Macular Edema Secondary to RVOChoroidal Neovascularization, Age-related Macular DegenerationNCT00379795Genentech, Inc.853